For years, semaglutide was framed as a powerful tool for diabetes and weight loss. Now cardiologists are confronting a more ...

Novo Nordisk’s Wegovy weight loss pill hit U.S. pharmacies this week. Here’s how it works, who qualifies, how to take it, ...

Please provide your email address to receive an email when new articles are posted on . Adults with overweight or obesity plus preexisting CVD had a reduction in CV event risk with semaglutide in ...

The use of semaglutide for non-diabetic obese patients with cardiovascular disease was first reported to be associated with significant benefit in the SELECT trial, where major adverse cardiovascular ...

Semaglutide is at least as effective at preventing heart attacks and other cardiac events as well as death in people with impaired kidney function as it is in those with normal kidney function The ...

People who stop taking GLP-1 drugs such as Ozempic and Wegovy for weight loss are projected to regain their shed pounds ...

In a recent study published in Nature Medicine, researchers evaluated the efficacy of semaglutide in patients with the obesity phenotype of heart failure and preserved ejection fraction (HFpEF). Study ...

Findings from a new meta-analysis suggest that if the drugs aren’t continued, other weight management interventions may be ...

MEDVi, a telehealth platform serving more than 100,000 patients, today announced continued nationwide momentum as ...

For those with type 2 diabetes who have knee osteoarthritis, getting a knee replacement can be difficult because they are ...

A new study led by a researcher at University College London (UCL) suggests that the anti-obesity drug semaglutide may reduce ...